Dow Inc. 2025 Q3 10-Q Filing Summary
Business Context and Reporting Period
This is a combined Form 10-Q for Dow Inc. and its wholly-owned subsidiary, The Dow Chemical Company (TDCC), for the quarterly period ended September 30, 2025. Dow operates as a large accelerated filer in the global chemicals industry. The reporting period reflects continued challenging macroeconomic conditions, including slower global GDP growth, industry overcapacity, and geopolitical volatility, which have negatively impacted sales prices and volumes across all segments.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | YTD 9M 2025 | YTD 9M 2024 |
|---|---|---|---|---|
| Net Sales | $9,973 million | $10,879 million | $30,508 million | $32,559 million |
| Net Income (Loss) Available to Dow Inc. | $62 million | $214 million | $(1,080) million | $1,169 million |
| Diluted EPS | $0.08 | $0.30 | $(1.53) | $1.65 |
| Operating Cash Flow (Continuing Ops) | $1,130 million (Q3) | $800 million (Q3) | $764 million (9M) | $2,092 million (9M) |
| Free Cash Flow (Non-GAAP) | N/A | N/A | $(1,147) million | $(81) million |
| Cash and Cash Equivalents | $4,609 million | $2,883 million | $4,609 million | $2,883 million |
| Net Debt (Non-GAAP) | $13,149 million | $13,771 million | $13,149 million | $13,771 million |
| Capital Expenditures | $564 million | $736 million | $1,911 million | $2,173 million |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 8% in Q3 and 6% YTD compared to the prior year, driven by an 8% decrease in local prices and a 1% decrease in volume. All three operating segments (Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, Performance Materials & Coatings) reported sales declines.
- Profitability Impact: The company reported a net loss of $1.08 billion for the first nine months of 2025, compared to net income of $1.17 billion in the same period last year. This was primarily due to margin compression, lower equity earnings from joint ventures (specifically Sadara and EQUATE), and significant restructuring charges.
- Restructuring Charges: The company recorded $822 million in "Restructuring and asset related charges - net" for the nine months ended September 30, 2025. This includes a $207 million charge in Q1 for severance and a $591 million charge in Q2 for asset write-downs and exit costs related to the 2025 Restructuring Program.
- Divestitures: The company recognized a $103 million gain from the sale of its soil fumigation product line (Q2) and a $110 million gain from the sale of its interest in DowAksa (Q3).
- Dividend Reduction: On July 24, 2025, the Board declared a quarterly dividend of $0.35 per share, a 50% reduction from the previous quarter's $0.70, in response to the industry downturn.
Guidance, Outlook, and Risks
- Capital Expenditure Outlook: Dow reduced its expected full-year 2025 capital expenditures to approximately $2.5 billion (down from $3.5 billion), primarily due to the decision to delay construction of the Path2Zero project in Fort Saskatchewan, Alberta, until market conditions improve.
- Restructuring Actions: The 2025 Restructuring Program includes the shutdown of an ethylene facility in Böhlen, Germany; chlor-alkali and vinyl assets in Schkopau, Germany; and a siloxanes plant in Barry, UK. These actions are expected to be completed over the next four years.
- Liquidity: The company maintains strong liquidity with $14.5 billion in cash and committed credit facilities. No substantive long-term debt maturities are due until 2027.
- Key Risks:
- Macroeconomic Conditions: Persistent slower global GDP growth and industry overcapacity continue to pressure prices and volumes.
- Geopolitical & Trade: Ongoing conflicts (Russia-Ukraine, Middle East) and shifting U.S. trade policies/tariffs create supply chain and market volatility.
- Joint Venture Performance: Continued losses at Sadara Chemical Company and EQUATE Petrochemical Company negatively impact equity earnings.
- Legal & Environmental: Significant exposure remains regarding asbestos-related litigation (Union Carbide) and environmental remediation costs, though no material adjustments were made to accruals in Q3.
Investor Verification Checklist
- Restructuring Execution: Verify the timeline and cost realization of the announced asset shutdowns in Europe and the UK to ensure projected cost savings are achieved.
- Joint Venture Turnaround: Monitor the operational recovery and financial performance of Sadara and EQUATE joint ventures, which are currently generating significant equity losses.
- Path2Zero Project Status: Track the decision-making process regarding the delayed Path2Zero project and the specific market conditions required to resume construction.
- Dividend Sustainability: Assess the company's ability to maintain the reduced dividend level of $0.35 per share given the current margin compression and cash flow environment.
- Legal Contingencies: Review updates on the Dow v. Nova Chemicals litigation regarding the ethylene asset in Alberta, where a judgment of approximately $1.3 billion is pending appeal and potential stay.